Nonetheless, despite these advancements, the heterogeneous nature of PSMA expression among prostate cancer patients poses challenges, necessitating a comprehensive review to synthesize existing evidence and guide future research endeavors. This evidence concerns the gene FOLH1 and prostate cancer.